Abdul-Mutakabbir JC, Alosaimy S, Morrisette T, et al. Cefiderocol: a novel siderophore cephalosporin against multidrug-resistant gram-negative pathogens. Pharmacotherapy. 2020;40:1228-1247.
AVYCAZ^® (ceftazidime and avibactam) [prescribing information]. Allergan USA, Inc. Approved 2015. Revised December 2020.
Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomized, open-label, multicenter, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2020. doi: 10.1016/S1473-3099(20)30796-9. [Epub ahead of print].
Ibn Saied W, Mourvillier B, Cohen Y, et al. A comparison of the mortality risk associated with ventilator-acquired bacterial pneumonia and nonventilator ICU-acquired bacterial pneumonia. Crit Care Med. 2019;47:345-352.
Kolleff MH, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomized, controlled, double-blind, phase 2, noninferiority trial. Lancet Infect Dis. 2019;19:1299-1311.
Poulakou G, Lagou S, Karageorgopoulos DE, et al. New treatments of multidrug-resistant Gram-negative ventilator-associated pneumonia. Ann Transl Med. 2018;6:423.
Sader HS, et al. Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17). J Antimicrob Chemother. 2018;73:3053-3059.
Titov I, Wunderink RG, Roquilly A, et al. A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI-2 Study). Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa803. [Epub ahead of print].
Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J. 2017;50:1700582.
Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285-295.
Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomized, double-blind, phase 3 noninferiority trial. Lancet Infect Dis. 2020. doi: 10.1016/S1473-3099(20)30731-3. [Epub ahead of print].
ZERBAXA^® (ceftolozane and tazobactam) [prescribing information]. Merck & Co., Inc. Approved 2014. Revised September 2020.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Matteo Bassetti, MD, PhD

Professor of Infectious Diseases
Department of Health Science
University of Genoa
Head, Infectious Diseases Clinic
Hospital Policlinico San Martino – IRCCS
Genoa, Italy

Disclosures

Disclosure: Matteo Bassetti, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Astellas; Bayer; Gilead; Menarini; MSD; Pfizer
Served as a speaker or a member of a speakers bureau for: Astellas; Bayer; Gilead; Menarini; MSD; Pfizer
Received grants for clinical research from: Astellas; Bayer; Gilead; Menarini; MSD; Pfizer

Keith Kaye, MD, MPH

Professor of Medicine
Director of Research
Division of Infectious Diseases
University of Michigan
Ann Arbor, Michigan

Disclosures

Disclosure: Keith Kaye, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Merck; Shionogi Inc.
Received grants for clinical research from: Merck
Owns stock, stock options, or bonds from: Merck

Editor

Roderick Smith, MS

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships.

CME, CE Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LL

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC / CE

Expert to Expert: Updates on New Treatments for Nosocomial Pneumonia

Authors: Matteo Bassetti, MD, PhD; Keith Kaye, MD, MPH
CME / ABIM MOC / CE Released: 1/20/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 1/20/2022

Start Activity

Target Audience and Goal Statement

This activity is intended for infectious disease and critical care specialists.

The goal of this activity is to increase clinicians' knowledge on the latest data for new or emerging antibiotics for the treatment of nosocomial pneumonia (NP).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Mechanisms of action of newer antibiotics for the treatment of NP
- Data for new or emerging therapies in the treatment of NP
Have greater confidence regarding their ability to
- Collaborate with the interprofessional healthcare team to optimize the care of patients with NP

Disclosures

Faculty

Matteo Bassetti, MD, PhD

Professor of Infectious Diseases
Department of Health Science
University of Genoa
Head, Infectious Diseases Clinic
Hospital Policlinico San Martino – IRCCS
Genoa, Italy

Disclosures

Disclosure: Matteo Bassetti, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Astellas; Bayer; Gilead; Menarini; MSD; Pfizer
Served as a speaker or a member of a speakers bureau for: Astellas; Bayer; Gilead; Menarini; MSD; Pfizer
Received grants for clinical research from: Astellas; Bayer; Gilead; Menarini; MSD; Pfizer

Keith Kaye, MD, MPH

Professor of Medicine
Director of Research
Division of Infectious Diseases
University of Michigan
Ann Arbor, Michigan

Disclosures

Disclosure: Keith Kaye, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Merck; Shionogi Inc.
Received grants for clinical research from: Merck
Owns stock, stock options, or bonds from: Merck

Editor

Roderick Smith, MS

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships.

CME, CE Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LL

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-21-024-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Infectious Diseases

CME / ABIM MOC / CE

Expert to Expert: Updates on New Treatments for Nosocomial Pneumonia

Authors: Matteo Bassetti, MD, PhD; Keith Kaye, MD, MPHFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 1/20/2021

Valid for credit through: 1/20/2022

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

Download Now

CME / ABIM MOC / CE Information

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Matteo Bassetti, MD, PhD

Keith Kaye, MD, MPH

Editor

Roderick Smith, MS

CME, CE Reviewer

Robert Morris, PharmD

Peer Reviewer

CME / ABIM MOC / CE

Expert to Expert: Updates on New Treatments for Nosocomial Pneumonia

Target Audience and Goal Statement

Disclosures

Faculty

Matteo Bassetti, MD, PhD

Keith Kaye, MD, MPH

Editor

Roderick Smith, MS

CME, CE Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

For Pharmacists

Instructions for Participation and Credit

Expert to Expert: Updates on New Treatments for Nosocomial Pneumonia